A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of avonex in patients with multiple sclerosis

Clinical Therapeutics

Volumn 26, Issue 4, 2004, Pages 511-521

  Phillips, J Theodore ^a   Rice, George ^b   Frohman, Elliot ^c   Vande Gaer, Luc ^d   Scott, Thomas ^e   Haas, Judith ^f   Eggenberger, Eric ^g   Freedman, Mark S ^h   Stuart, William ⁱ   Cunha, Luis ^j   Jacobs, Lawrence ^k   Oger, Joel ^l   Arnold, Douglas ^m   Murray, Jock ⁿ   DiBiase, Mary ^o   Jethwa, Vijay ^o   Goelz, Susan ^o  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d Multiple Sclerosis and Rehab Center   (Belgium)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f Judisches Krankenhaus Berlin   (Germany)

^g East Lansing   (United States)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ MS Center of Atlanta   (United States)

^j CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^k BUFFALO GENERAL HOSPITAL   (United States)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m MCGILL UNIVERSITY   (Canada)

ⁿ DALHOUSIE UNIVERSITY   (Canada)

^o BIOGEN   (United States)

more..

Author keywords

Immunogenicity; Interferon beta 1a; Liquid Avonex; Multiple sclerosis; Neutralizing antibodies; Prefilled syringe

Indexed keywords

BETA1A INTERFERON; HUMAN SERUM ALBUMIN; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; LYOPHILISATE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; RELAPSE; SYRINGE;

EID: 2342637729     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90053-7     Document Type: Article

References (34)

1. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) [published correction appears in Ann Neurol. 1996;40:480]. Ann Neurol. 1996;39:285-294.
2. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol. 1998;43:79-87.
3. Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon β-1a. Multiple Sclerosis Collaborative Research Group. Neurology. 2000;55:185-192.
4. Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 1999;53:1698-1704.
5. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol. 2000;48:885-892.
6. Schellekens H. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther. 2002;24:1720-1740.
7. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology. 1996;47:889-894.
8. The PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS [published correction appears in Neurology. 2001;57:1146]. Neurology. 2001;56:1628-1636.
9. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362:1184-1191.
10. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: A follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry. 2002;73:148-153.
11. Panitch H, Goodin DS, Francis G, et al, for the EVIDENCE Study Group. Evidence of Interferon Dose-response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002;59:1496-1506.
12. Clanet M, Radue EW, Kappos L, et al, for the European IFNβ-1a (Avonex) Dose-Comparison Study Investigators. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology. 2002;59:1507-1517.
13. Herndon RM, Jacobs LD, Coats ME, et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MS Care. [serial online] 1999;2:1-6. Available at: http://mscare.org. Accessed November 22, 2002.
14. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898-904.
15. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology. 1998;50:1266-1272.
16. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:655-661.
17. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 1983;13:227-231.
18. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [published correction appears in Neurology. 2002;59:480]. Neurology. 2002;58:169-178.
19. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol. 1986;119:558-573.
20. WHO Expert Committee on Biological Standardisation. Thirty-Fifth Report. WHO Technical Report Series 725. Geneva, Switzerland: World Health Organization; 1985.
21. Grossberg SE, Kawade Y, Kohase M, et al. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bio-assay systems. J Interferon Cytokine Res. 2001;21:729-742.
22. Antonelli G, Simeoni E, Bagnato F, et al. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci. 1999;168:131-136.
23. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology. 2003;60:634-639.
24. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol. 2000;48:706-712.
25. Pachner AR. Anti-IFNβ antibodies in IFNβ-treated MS patients: Summary. Neurology. 2003;61(Suppl 5):S1-S5.
26. Deisenhammer F, Reindl M, Harvey J, et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology. 1999;52:1239-1243.
27. Williams GJ, Witt PL. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron® and AVONEX™. J Interferon Cytokine Res. 1998;18:967-975.
28. Ryff JC. Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interferon Cytokine Res. 1997;17(Suppl 1):S29-S33.
29. Haselbeck A. Epoetins: Differences and their relevance to immunogenicity. Curr Med Res Opin. 2003;19:430-432.
30. Milo R, Panitch H. Glatiramer acetate or interferon-β for multiple sclerosis? A guide to drug choice. CNS Drugs. 1999;11:289-306.
31. Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res. 1997;14:1472-1478.
32. Avonex [package insert]. Cambridge, Mass: Biogen, Inc; 2003.
33. Betaseron [package insert]. Wayne, NJ: Berlex Laboratories, Inc; 2003.
34. Rebif [package insert]. Rockland, Mass: Serono, Inc; 2003.